Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

Mammoth Biosciences, Inc., a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, today announced new ...

( MENAFN - EIN Presswire) The Interventional Cardiovascular Devices market is projected to expand at a CAGR of 4.66%, reaching a market size of USD 69.1 billion by 2032 ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.